Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
Plos One|March 3, 2012
Using PCR-based detection and genotyping to trace Streptococcus salivarius meningitis outbreak strain to oral flora of radiology physician assistantVelusamy Srinivasan, Robert E Gertz, Patricia L Shewmaker, et al.
JAMA|June 10, 2010
Infection control assessment of ambulatory surgical centersMelissa K Schaefer, Michael Jhung, Marilyn Dahl, et al.
Cancer Science|March 17, 2021
Safety and antitumor activity of acalabrutinib for relapsed/refractory B-cell malignancies: A Japanese phase I studyKoji Izutsu, Kiyoshi Ando, Daisuke Ennishi, et al.
British Journal of Clinical Pharmacology|April 25, 2022
Bioavailability of acalabrutinib suspension delivered via nasogastric tube in the presence or absence of a proton pump inhibitor in healthy subjectsShringi Sharma, Xavier Pepin, Jean Cheung, et al.
The American Journal of Psychiatry|May 2, 2006
Treating disturbances in the relationship between mothers with bulimic eating disorders and their infants: a randomized, controlled trial of video feedbackAlan Stein, Helen Woolley, Robert Senior, et al.
Journal for Immunotherapy of Cancer|March 2, 2020
Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancerMichael Overman, Milind Javle, Richard E Davis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2021
Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept StudyMatthew H Taylor, Courtney B Betts, Lauren Maloney, et al.
The Lancet. Haematology|November 4, 2021
Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 studyToby A Eyre, Anna Schuh, William G Wierda, et al.
Haematologica|March 18, 2021
Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemiaKerry A Rogers, Philip A Thompson, John N Allan, et al.
Haematologica|September 30, 2021
Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patientsJennifer R Brown, John C Byrd, Paolo Ghia, et al.
Pageof 6